

Over the past 12 months, $GMAB has been mentioned 23 times by 2 distinct FinTwit voices, with the first mention appearing on September 29, 2025. Jacob Plieth (@jacobplieth) dominates the conversation with 24 mentions, while Adam Feuerstein (@adamfeuerstein) contributed 1 mention. The most recent discussion occurred on July 17, 2026, situating $GMAB within biotech-focused commentary.
The mentions of $GMAB appear primarily in the context of clinical development discussions and mechanism-of-action questions. Jacob Plieth has been the consistent voice discussing the company, engaging in conversations about clinical trial design choices and therapeutic mechanisms related to HPV and other indications. The ticker has been cited alongside related biotech companies including $BCAX, $JNJ, and $MRUS in discussions about clinical trial strategies and drug efficacy claims.
@jacobplieth (Jacob Plieth) mentions $GMAB most — 24 mentions in the past 12 months.
The earliest tracked mention of $GMAB in the Surfaced archive was on Sep 29, 2025.
2 FinTwit voices have mentioned $GMAB 23 times in the past 12 months.
$GMAB is mentioned most by Biotech voices on Surfaced.
